Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Teva Pharmaceutical Industries ADR Representing One TEVA

Healthcare
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.


NYSE:TEVA - Post by User

Teva Pharmaceutical Industries ADR Representing One
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(232)
•••
Post by whytestockson Jan 31, 2024 2:15pm
107 Views
Post# 35855396

Teva Reports Growth in Fourth Quarter and Full Year 2023

Teva Reports Growth in Fourth Quarter and Full Year 2023
Just In: $TEVA Teva Reports Growth in Fourth Quarter and Full Year 20232023 revenues of $15.8 billion reflect an increase of 7% in local currency terms, compared to 2022 AUSTEDO &#xAE; - exceeding $1.2 billion in annual revenues, up 28% from 2022; strong growth expected to continue in 2024 with expected revenues of ~$1.5 billion; AJOVY &#xAE; - globa...TEVA - Teva Reports Growth in Fourth Quarter and Full Year 2023

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities